You are here: Industry Insights > Ridgeback

News List

Merck and Ridgeback make pact with UNICEF for antiviral COVID-19 medicine supply CPhIonline
January 20, 2022
The agreement will enable millions of patients in more than 100 low- and middle-income countries to gain access to molnupiravir.
Merck, Ridgeback Ink Molnupiravir Supply Agreement with UNICEF contractpharma
January 18, 2022
Allocate 3 million courses of the oral antiviral to be provided in first half of 2022 for use in low- and middle-income countries.
Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world WorldPharmaNews
November 16, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA)...
Merck signs $1.2bn supply deal with US for antiviral molnupiravir pharmaceutical-technology
June 10, 2021
Merck (MSD) has signed an agreement, valued at about $1.2bn, with the US Government to supply its investigational oral antiviral candidate, molnupiravir (MK-4482) to treat mild to moderate Covid-19.
Ridgeback and Merck report preliminary data from Covid-19 trial pharmaceutical-technology
March 09, 2021
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational oral antiviral agent molnupiravir EIDD-2801/MK-4482 for Covid-19.
Ridgeback Announces Initiation of Expanded Access Protocol for Ebola Treatment americanpharmaceuticalreview
August 31, 2020
Ridgeback Biotherapeutics announced the implementation of an expanded access protocol to ensure rapid access to its Ebola treatment, ansuvimab, in the Democratic Republic of the Congo (DRC).
Merck and Ridgeback Bio Collaborate contractpharma
May 28, 2020
Merck and Ridgeback Biotherapeutics LP, a closely held biotechnology company, have entered into a collaboration agreement to develop EIDD-2801.
Ridgeback Biotherapeutics Breakthrough Therapy Designation for mAb114 americanpharmaceuticalreview
September 10, 2019
Ridgeback Biotherapeutics announced the Food and Drug Administration (FDA) has recently granted mAb114, an experimental treatment for Ebola, Breakthrough Therapy designation.